Stock Rating Downgrade
Reflecting eroding fundamentals and low Appreciation Potential, the Value Trend Rating for ADMA Biologics Inc (NASDAQ: ADMA) weakened of late. ADMA’s current Value Trend Rating is D and the prior Rating was C. Details supporting this lower rating are included in our next report.
Recent Price Action
ADMA Biologics Inc (NASDAQ: ADMA) stock closed at $4.40 on 1/5/24 after a decline of -2.9%. However, trading volume in this decline was below average at 76% of normal. The stock has declined -2.0% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
ADMA’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to be an important Value Builder.
ADMA Biologics has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing contradictory signals. ADMA Biologics has a poor Appreciation Score of 18 but a slightly positive Power Rating of 69, and the Negative Value Trend Rating results.
Be the first to comment